Ovarian Sertoli--Leydig cell tumors: MRI findings and pathological correlation Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, October 27, 2013

Ovarian Sertoli--Leydig cell tumors: MRI findings and pathological correlation



open access

Background

To investigate the magnetic resonance imaging (MRI) characteristics of ovarian Sertoli-Leydig cell tumors (SLCT).

Methods

The clinical, MRI and pathological findings of five cases of SLCT were reviewed retrospectively. MRI appearances of tumors including laterality, shape and size, architecture, wall, septa and vegetation, signal intensity and contrast-enhancement pattern were evaluated and correlated with pathological findings.

Results

Two tumors were solid which appeared as low signal intensity on T1-weighted imaging (T1WI) and moderate on T2-weighted imaging (T2WI) with multiple small cysts in one of them. The remaining three SLCT were multilocular cystic with the irregularly thickened wall and septa, and with solid area and mural nodules in one of them. The cystic components had the same signal intensity as urine. All the solid components were intensely enhanced after administration of contrast medium. All five tumors were pathologically intermediate differentiation and at FIGO stage I.

Conclusions

SLCT demonstrate variable MRI morphological appearances. However, the irregularly thickened wall and septa, the moderate T2WI signal intensity and obvious enhancement in the solid components are three MRI features.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production. 

 Background

Sertoli-Leydig cell tumors (SLCT) of ovary are a rare type but well defined clinicopathologic entity of sex cord-stromal tumors, accounting for less than 0.5% of ovarian neoplasms [1]. These tumors are histopathologically characterized by the presence of variable proportions of Sertoli and Leydig cells. Most SLCT occur in young women and are at stage I (International Federation of Gynecology and Obstetrics, FIGO) [2]. Conservative surgery is acceptable for young patients who wish to preserve fertility without compromising 5-year disease-specific
survival [3]. Some clinicopathological studies of SLCT have been reported. To our knowledge, however, only three imaging case reports have been published [4-6]. The present study described the magnetic resonance imaging (MRI) appearances of five patients with SLCT by correlated with pathological findings, with the aim to be familiar with the imaging
appearances of this entity and improve the accuracy of preoperative diagnosis.....

 

1 comment :

  1. Sertoli Leydig cell tumor is a sex cord-gonadal stromal tumor normally occurring only in the testis, but also in the ovary.

    Besides an examination of family history, you may want to consider BRCA testing. Sertoli Leydig Cell tumors can be caused by genetic mutation as some studies show there is mutation of DICER1 (small interfering RNA regulating enzymes or SiRNA's) and sometimes BRCA genes.

    In regards to the BRCA role, a cell function analysis clinician feels genomic fidelity genes are fundamental to cancer. Their failure, as with BRCA 1 and 2 or Mismatch repair (as in Lynch Syndrome), render genetic mutations unprepared and detrimental. BRCA mutations are not only associated with breast and ovarian but other cancers as well.

    The identification of BRCA mutation would have impactions for PARP inhibitor therapy.

    ReplyDelete

Your comments?

Note: Only a member of this blog may post a comment.

1 comment :

  1. Sertoli Leydig cell tumor is a sex cord-gonadal stromal tumor normally occurring only in the testis, but also in the ovary.

    Besides an examination of family history, you may want to consider BRCA testing. Sertoli Leydig Cell tumors can be caused by genetic mutation as some studies show there is mutation of DICER1 (small interfering RNA regulating enzymes or SiRNA's) and sometimes BRCA genes.

    In regards to the BRCA role, a cell function analysis clinician feels genomic fidelity genes are fundamental to cancer. Their failure, as with BRCA 1 and 2 or Mismatch repair (as in Lynch Syndrome), render genetic mutations unprepared and detrimental. BRCA mutations are not only associated with breast and ovarian but other cancers as well.

    The identification of BRCA mutation would have impactions for PARP inhibitor therapy.

    ReplyDelete

Your comments?

Note: Only a member of this blog may post a comment.